Clinical Practice

Episodes 1-16 of 91

- Javed Butler, MD, MPH, MBA
  Peer
- Piotr Ponikowski, MD, PHD, FESC, FHFA
  Peer
- Gerasimos Filippatos, MD, FESC, FHFA
  Peer
3
CME/CE
AHA 2020: Neue Erkenntnisse zu Eisenmangel und Herzinsuffizienz
AHA 2020: Neue Erkenntnisse zu Eisenmangel und Herzinsuffizienz
0.25 credits
AHA 2020: Neue Erkenntnisse zu Eisenmangel und Herzinsuffizienz
0.25 credits
- Michael Böhm, MD, FESC
  Peer
1
Global Heart Failure Academy
AFFIRM-AHF: Wichtige Punkte
AFFIRM-AHF: Wichtige Punkte
AFFIRM-AHF: Wichtige Punkte
- Michael Böhm, MD, FESC
  Peer
6
Global Heart Failure Academy
CARE HK bei HF: Entwurf einer Studie aus der Praxis zur Identifizierung von Barrieren für die leitliniengesteuerte RAASi-Therapie
CARE HK bei HF: Entwurf einer Studie aus der Praxis zur Identifizierung von Barrieren für die leitliniengesteuerte RAASi-Therapie
CARE HK bei HF: Entwurf einer Studie aus der Praxis zur Identifizierung von B...
- Javed Butler, MD, MPH, MBA
  Peer
- Piotr Ponikowski, MD, PHD, FESC, FHFA
  Peer
- Gerasimos Filippatos, MD, FESC, FHFA
  Peer
8
CME/CE
AHA 2020: New Insights on Iron Deficiency and Heart Failure
AHA 2020: New Insights on Iron Deficiency and Heart Failure
0.25 credits
AHA 2020: New Insights on Iron Deficiency and Heart Failure
0.25 credits
- Eliot Brinton, MD, FAHA, FNLA
  Peer
- Erin D. Michos, MD, MHS, FACC, FAHA, FASE
  Peer
13
CME/CE Broadcast Replay
CME/CE Broadcast Replay
The New Role of Omega-3 Fatty Acids in Reducing ASCVD Risk in Women: Expert Dialogue
The New Role of Omega-3 Fatty Acids in Reducing ASCVD Risk in Women: Expert Dialogue
0.75 credits
The New Role of Omega-3 Fatty Acids in Reducing ASCVD Risk in Women: Expert D...
0.75 credits
- Ewa A. Jankowska, MD, PhD, FESC
  Peer
4
Global Heart Failure Academy
AFFIRM-AHF: Key Takeaways
AFFIRM-AHF: Key Takeaways
AFFIRM-AHF: Key Takeaways
- Stefan D. Anker, MD, PhD
  Peer
- Javed Butler, MD, MPH, MBA
  Peer
- Ewa A. Jankowska, MD, PhD, FESC
  Peer
- Josep Comin-Colet, MD, PhD
  Peer
9
Global Heart Failure Academy
Late-breaking First Response on AFFIRM-AHF
Late-breaking First Response on AFFIRM-AHF
Late-breaking First Response on AFFIRM-AHF
- Eliot Brinton, MD, FAHA, FNLA
  Peer
- Erin D. Michos, MD, MHS, FACC, FAHA, FASE
  Peer
7
CME/CE
0.25 credits
Prevention of ASCVD in Women Through Lipid Management in the New Era
0.25 credits
- Javed Butler, MD, MPH, MBA
  Peer
- Peter van der Meer, MD, PhD
  Peer
8
CME/CE
Common Misconceptions About Iron Deficiency in Heart Failure and What to Do About It
Common Misconceptions About Iron Deficiency in Heart Failure and What to Do About It
0.25 credits
Common Misconceptions About Iron Deficiency in Heart Failure and What to Do A...
0.25 credits
- Mikhail Kosiborod, MD
  Peer
6
Global Heart Failure Academy
CARE HK in HF: Designing a Real-world Study to Identify Barriers to Guideline-directed RAASi Therapy
CARE HK in HF: Designing a Real-world Study to Identify Barriers to Guideline-directed RAASi Therapy
CARE HK in HF: Designing a Real-world Study to Identify Barriers to Guideline...
- George Bakris, MD
  Peer
- Matthew R. Weir, MD
  Peer
- Faiez Zannad, MD, PhD
  Peer
8
CME/CE
Potassium Management Made Easy
Potassium Management Made Easy
0.25 credits
Potassium Management Made Easy
0.25 credits
- Austin G. Stack, MBBCh, MD, MSc, FASN, FRCPI
  Peer
- Mikhail Kosiborod, MD
  Peer
19
CME/CE
Management of Heart Failure: Time to Consider New Options?
Management of Heart Failure: Time to Consider New Options?
0.25 credits
Management of Heart Failure: Time to Consider New Options?
0.25 credits
- Michel Farnier, MD, PhD
  Peer
- Børge G. Nordestgaard, MD, DMSc
  Peer
7
CME/CE
Omega-3 Fatty Acids in Patients with ASCVD Risk: The Role of Icosapent Ethyl (IPE)
Omega-3 Fatty Acids in Patients with ASCVD Risk: The Role of Icosapent Ethyl (IPE)
0.75 credits
Omega-3 Fatty Acids in Patients with ASCVD Risk: The Role of Icosapent Ethyl ...
0.75 credits
- Christopher P. Cannon, MD
  Peer
- Samuel Dagogo-Jack, MD, DSc
  Peer
8
CME/CE
Is It Time to Change Your Treatment Strategy for Type 2 Diabetes Patients with CV Risks?
Is It Time to Change Your Treatment Strategy for Type 2 Diabetes Patients with CV Risks?
0.25 credits
Is It Time to Change Your Treatment Strategy for Type 2 Diabetes Patients wit...
0.25 credits
- Javed Butler, MD, MPH, MBA
  Peer
7
CME/CE
Mr. Jackson Moves to Town: Overcoming Challenges to Optimizing RAASi Therapy
Mr. Jackson Moves to Town: Overcoming Challenges to Optimizing RAASi Therapy
0.25 credits
Mr. Jackson Moves to Town: Overcoming Challenges to Optimizing RAASi Therapy
0.25 credits
- Ewa A. Jankowska, MD, PhD, FESC
  Peer
- Stefan D. Anker, MD, PhD
  Peer
15
CME/CE
Beyond Anemia: Understanding the Significance and Treatment of Iron Deficiency
Beyond Anemia: Understanding the Significance and Treatment of Iron Deficiency
0.25 credits
Beyond Anemia: Understanding the Significance and Treatment of Iron Deficiency
0.25 credits